Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

281 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quantifying Antibody Persistence After a Single Dose of COVID-19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach.
Dari A, Boulton M, Neyens M, Le Gars M, Valenzuela B, Shukarev G, Cárdenas V, Ruiz-Guiñazú J, Sadoff J, Hoetelmans RMW, Ruixo JJP. Dari A, et al. Among authors: cardenas v. Clin Pharmacol Ther. 2023 Feb;113(2):380-389. doi: 10.1002/cpt.2796. Epub 2022 Dec 9. Clin Pharmacol Ther. 2023. PMID: 36377532 Free PMC article.
Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S.
Struyf F, Hardt K, Van Rampelbergh R, Shukarev G, Inamdar A, Ruiz-Guiñazú J, van Paassen V, Anaya-Velarde L, Diba C, Ceuppens M, Cardenas V, Soff GA, Pragalos A, Sadoff J, Douoguih M. Struyf F, et al. Among authors: cardenas v. Vaccine. 2023 Aug 23;41(37):5351-5359. doi: 10.1016/j.vaccine.2023.07.013. Epub 2023 Jul 28. Vaccine. 2023. PMID: 37517912 Free article.
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial.
Le Gars M, Sadoff J, Cárdenas V, Heerwegh D, Tesfaye F, Roey GV, Spicer C, Matias SS, Crayne O, Kamphuis T, Struyf F, Schuitemaker H, Douoguih M. Le Gars M, et al. Among authors: cardenas v. Vaccine. 2024 Jul 25;42(19):3938-3952. doi: 10.1016/j.vaccine.2024.03.079. Epub 2024 Jun 25. Vaccine. 2024. PMID: 38918103 Free article. Clinical Trial.
Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26-vectored vaccines.
Kristyanto H, Slaets L, Braams E, Scheys I, Heesbeen R, Cárdenas V, Shukarev G, Scheper G, Sadoff J, Lühn K, Schuitemaker H, Struyf F, Hendriks J. Kristyanto H, et al. Among authors: cardenas v. J Thromb Haemost. 2024 Sep 13:S1538-7836(24)00536-1. doi: 10.1016/j.jtha.2024.08.019. Online ahead of print. J Thromb Haemost. 2024. PMID: 39278600 Free article.
Ad26.COV2.S COVID-19 vaccine safety and immunogenicity in adolescents 16-17 years of age.
Ruiz-Guiñazú J, Le Gars M, Cárdenas V, Vaissière N, Sadoff J, Truyers C, Hendriks J, Scheper G, de Groot AM, Struyf F, Schuitemaker H, Douoguih M. Ruiz-Guiñazú J, et al. Among authors: cardenas v. J Pediatric Infect Dis Soc. 2024 Sep 28:piae098. doi: 10.1093/jpids/piae098. Online ahead of print. J Pediatric Infect Dis Soc. 2024. PMID: 39340467 No abstract available.
281 results